Travoprost--a new @entity3009 analogue for the treatment of XXXX .

@entity1 @entity6839 @entity726 @entity3009 @entity2790 @entity3774 @entity551
Travoprost, a highly selective and potent analogue of the @entity3009 @entity3774 , has recently been approved and marketed as a topical @entity551 agent for the treatment of @entity2790 and @entity726 . Following absorption into the eye, the free acid form of travoprost interacts with the endogenous FP prostanoid receptor to enhance aqueous humor outflow and lower intraocular pressure (IOP). Travoprost is distinguished from other marketed @entity3009 analogues in that it is a full agonist at the @entity3009 receptor. It is also highly selective with little or no affinity for other prostanoid or non-prostanoid receptors in the eye. Travoprost provides robust lowering of IOP with little diurnal fluctuation and results in @entity551 in a large percentage of @entity1 . In controlled clinical trials, travoprost 0.004% o.d. used as monotherapy produced greater IOP reduction than @entity6839 0.5% b.i.d. and equal or greater reduction than latanoprost 0.005%o.d. Travoprost 0.004% was also shown to be an effective adjunctive agent offering an additional 5 - 7 mmHg IOP reduction in @entity1 inadequately controlled on @entity6839 0.5%. Subgroup analysis of a large Phase III trial revealed travoprost 0.004% to be significantly more effective at lowering IOP in African American @entity1 by almost 2 mmHg compared to non-African Americans. Moreover, a higher percentage of African American @entity1 responded to travoprost 0.004% and reached lower target pressures than with either latanoprost 0.005% or @entity6839 0.5%. Travoprost is a very stable compound, maintaining its efficacy following exposure to extremely low and high temperatures, repeated freezing and thawing and exposure to light. Throughout all clinical trials, travoprost was found to be safe and well-tolerated with very few (< 5%) discontinuations due to adverse events. Travoprost 0.004% represents a clinically significant advance for the treatment of @entity726 and @entity2790 , offering superior IOP reduction and diurnal control, especially among African American @entity1 , in a safe, well-tolerated, stable formulation.
